Real-World Experience with Pembrolizumab Treatment in Patients with Heavily Treated Recurrent Gynecologic Malignancies.

ABSTRACT:

Purpose

We evaluated the efficacy and safety of pembrolizumab in patients with recurrent gynecologic cancers in real-world practice.

Materials and methods

We conducted a retrospective, single-institution study of patients with recurrent gynecologic malignancies treated with pembrolizumab. The primary endpoints were the objective response rate (ORR) and safety.

Results

Thirty-one patients treated with pembrolizumab were included. The primary disease sites were the uterine cervix (n=18), ovaries (n=8), and uterine corpus (n=5). Fifteen of the 31 patients (48%) had an Eastern Cooperative Oncology Group performance status of ≥2. The median number of prior chemotherapy lines was 2 (range, 1-6), and 14 of 31 patients (45%) had received ≥ 3 prior lines of chemotherapy. The o

SUBMITTER: Choi MC 

PROVIDER: S-EPMC7515778 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature